Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The Download: a Nobel winner on AI, and the case for fixing everything

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: a Nobel winner on AI, and the case for fixing everything Date: 2026-05-12 12:10 Source: https://www.technologyreview.com/2026/05/12/1137103/the-download-nobel-winner-ai-maintenance-of-everything/ <p><em>This is today’s edition of </em><a href="https://forms.techn…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Attempts to remove Sam Altman from OpenAI were amateurish

    60% confidence
  • Maintainers haven't gotten the laurels they deserve

    60% confidence
  • Maintenance is a 'civilizational' act; taking responsibility for maintaining something — whether a motorcycle, a monument, or the planet — can be radical

    60% confidence
  • AI would give only a small boost to US productivity and would not eliminate the need for human work

    60% confidence
  • Sam Altman has a pattern of lying; Sutskever spent a year gathering proof of Altman's dishonesty

    60% confidence
  • Stewart Brand's vision of maintenance often feels solitary: profound, but more about personal fulfillment than tending to a shared world or making it better

    60% confidence
  • Elon Musk's hypocrisy over OpenAI becoming a for-profit company will undermine his courtroom battle with Sam Altman

    60% confidence
  • Two years after his cautious AI predictions, the data is still largely on his side despite significant technological advancement

    60% confidence
  • Daybreak will continuously secure software

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com